MenuMenu The de la Garza Law Group
Local 713-804-8670
Or Toll Free 844-784-1010
Local 713-804-8670
Or Toll Free 844-784-1010

Anti-nausea medication Zofran is tied to birth defects.

shutterstock_165659150-150x150.jpgZofran is an anti-nausea drug that's often prescribed for pregnant women suffering from morning sickness. But it now appears that taking Zofran while pregnant could seriously harm the fetus, according to a recent study in the American Journal of Obstetrics and Gynecology.

According to the study of 900,000 Danish women, the risk of infant heart defects doubled when pregnant women took
the drug. This is significant because an estimated 80 percent of pregnant women suffer from nausea and vomiting during preg-

nancy, and about 1 million of them have been taking Zofran (or a generic equivalent) each year.

Other women who have used the drug during pregnancy have reported babies born with cleft palates, club foot, mal- formed skulls, vision problems, and mental impairments.

GlaxoSmithKline, which manufactures Zofran, paid the government a significant fine in 2012 for illegal promotion of the drug and failing to report safety data. A number of lawsuits have now been filed by affected families as well.

Read More

No Comments

Leave a comment
Comment Information
Request A Consultation

How Can We Help?

Don't hesitate to get started. We offer free consultations for you to discuss your case with our attorneys and ask any questions. Call 713-804-8670 today, or reach out online to make an appointment.

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

The de la Garza Law Group 1616 S. Voss Rd., Suite 870 Houston, TX 77057 Phone: 713-804-8670 Fax: 713-784-1011 Houston Law Office Map

Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters.

Back to top